CLINICAL_TRIALS
trial_result
· 2013-11-01
Clinical Trial Update: Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks [Phase 1]
Summary
This Phase 1 study assesses the relative bioavailability of a single dose of BI 44370 tablet during and between migraine attacks.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Migraine Disorders | Phase 1 | Status: COMPLETED